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alterations were analyzed in relation to the patients’ tumor locations, demo-
graphics, and outcomes. We used multiple binary logistic regressions to as-
sess whether demographics and tumor location were predictive of the above 
alterations We also assessed the relationship between molecular alterations 
and outcomes when controlling for treatment and demographic variables. 
Among demographic variables, age predicted alterations in IDH1, EGFR, 
TERT, TP53, and PTEN. Frontal lobe tumors were more likely to be IDH1-
mutated, irrespective of patient age. Sex and race did not predict the inci-
dence of the molecular alterations of interest. Analysis of outcomes revealed 
that, when controlling for treatment and demographic variables, TERT pro-
moter mutations, TP53 nonsense mutations, and EGFR A289V were pre-
dictive of a decreased progression-free survival, while CDKN2A deletion, 
PTEN missense mutations, and EGFR A289V were predictive of decreased 
overall survival. Our experience highlights the importance of incorporating 
routine NGS in the management of patients with glioblastoma. More studies 
are required to evaluate the predictive and/or prognostic values of different 
molecular alterations.
PATH-36. MACHINE LEARNING TO DETECT GLIOMAS IN URINE-
BASED LIQUID BIOPSY
Yotaro Kitano1, Kosuke Aoki2, Takao Yasui3, Kazuya Motomura2, 
Fumiharu Ohka2, Kuniaki Tanahashi2, Masaki Hirano2,  
Tomohide Nishikawa2, Hiroyuki Shimizu2, Junya Yamaguchi2, 
Sachi Maeda1, Shintaro Yamazaki4, Toshihiko Wakabayashi2, and 
Atsushi Natsume2; 1Department of Neurosurgery, Nagoya University 
Graduate School of Medicine., Nagoya, Aichi, Japan, 2Department of 
Neurosurgery, Nagoya University Graduate School of Medicine., Nagoya, 
Japan, 3Department of Biomolecular Engineering, Nagoya University, 
Nagoya, Aichi, Japan, 4Department of Neurosurgery, Nagoya University 
Graduate School of Medicine, Nagoya, Japan
BACKGROUND: Diffuse gliomas are the most common primary ma-
lignant brain tumors, whose overall prognosis is quite dismal. Tumor-
cell-secreted extracellular vesicles (EVs) participate in physiological and 
pathological processes and have potential applications to diagnostics of 
malignant tumors including diffuse gliomas. Because urine is less invasive 
to collect, development of early diagnosis based on urine EVs is eagerly 
awaited. In this study, we captured urine EVs of patients with gliomas ef-
ficiently with the nanowire device and compared expression profile of 
microRNAs (miRNAs) within urine EVs with that of healthy donors to iden-
tify diagnostic accuracy by a machine learning algorithm.  METHODS: 62 
patients with diffuse gliomas, including 27 glioblastoma and 35 lower grade 
gliomas, and 100 healthy donors were analyzed, along with orthotopic 
transplant mouse model. Urinary EVs were obtained with the nanowire de-
vice which could collect EVs more efficiently than the conventional ultra-
centrifugation method (Yasui et.al., Science Adv.2017). Machine learning 
methods were performed to select the miRNAs which could distinguish 
patients with gliomas from healthy control.   RESULTS: More than 2400 
miRNAs were obtained from all urine samples. We identified miRNA panels 
that provided high diagnostic accuracy of diffuse gliomas (92.5%). There 
were 440 miRNAs whose expression increased by more than 1.5 fold (p< 
0.05) as compared to healthy donor samples (glioma-upregulated miRNAs), 
whereas the expression of 87 miRNAs decreased to less than 2/3-fold (p< 
0.05) (glioma-downregulated miRNAs). Mouse miRNAs which were hom-
ologous to glioma-upregulated and -downregulated miRNAs showed signifi-
cantly high and low level expressions, respectively, in glioma mouse models 
as compared to normal control mice, confirming the reliability of urine 
miRNA-based diagnosis. Furthermore, some of these glioma-upregulated 
miRNAs has been reported to be involved in tumor progression.   CON-
CLUSIONS: miRNAs obtained from urine could be biomarkers for detec-
tion of gliomas by machine learning and some of these could be associated 
with tumor progression.
PATH-37. PROGNOSTIC ROLE OF TERT PROMOTER MUTATIONS 
IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER 
GRADE GLIOMA
Hideyuki Arita1, Yuko Matsushita2, Makoto Ohno2, Yohei Miyake3, 
Kuniaki Saito4, Shota Tanaka5, Taishi Nakamura6, Kaoru Tamura7, 
Fumi Higuchi8, Eriel Sandika9, Hemragul Sabit10, Yasuhiko Hattori11,  
Shigeru Yamaguchi12, Yoshiko Okita13, Daisuke Sakamoto14, 
Junya Fukai15, Takehiro Uda16, Nohuhiro Hata17, Tomoko Shofuda18,  
Takashi Sasayama19, Kanji Mori20, Kazuhiko Kurozumi21, 
Masayuki Kanamori22, Hikaru Sasaki9, Haruhiko Kishima23,  
Yonehiro Kanemura24, Mitsutoshi Nakada10, Yukihiko Sonoda25, 
Motoo Nagane26, Keisuke Ueki8, Ryo Nishikawa27, Yoshitaka Narita2, and 
Koichi Ichimura28; 1National Cancer Center Research Institute, Chuo-ku, 
Tokyo, Japan, 2Department of Neurosurgery and Neuro-Oncology, 
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan, 3Saitama 
Medical University International Medical Center, Hidaka, Saitama, Japan, 
4Kyorin University Faculty of Medicine, Tokyo, Japan, 5Department of 
Neurosurgery, University of Tokyo, Bunkyo-Ku, Tokyo, Japan, 6Yokohama 
City University Graduate School of Medicine, Yokohama, Kanagawa, 
Japan, 7Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, 
Japan, 8Dokkyo Medical University, Mibu-Machi, Tochigi, Japan, 9Keio 
University School of Medicine, Tokyo, Tokyo, Japan, 10Department of 
Neurosurgery, Kanazawa University, Kanazawa, Japan, Kanazawa, Japan, 
11Department of Neurological Surgery, Okayama University Graduate 
School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 
Japan, 12Hokkaido University, Sapporo, Hokkaido, Japan, 13Department 
of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan, 
14Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, 
Japan, 15Department of Neurosurgery, Wakayama Medical University, 
Wakayama, Japan, 16Department of Neurosurgery, Osaka City University 
Graduate School of Medicine, Osaka, Japan, 17Kyushu University, 
Fukuoka-City, Fukuoka, Japan, 18Division of Stem Cell Research, 
Department of Biomedical Research and Innovation, Institute for Clinical 
Research, National Hospital Organization Osaka National Hospital, 
Osaka, Osaka, Japan, 19Department of Neurosurgery, Kobe University 
Graduate School of Medicine, Kobe, Hyogo, Japan, 20Department of 
Neurosurgery, Kansai Rosai Hospital, Amagasaki, Japan, 21Department of 
Neurological Surgery, Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan, 
22Department of Neurosurgery, Tohoku University Graduate School of 
Medicine, Sendai, Japan, 23Osaka University Graduate School of Medicine, 
Suita, Osaka, Japan, 24Division of Regenerative Medicine, Department 
of Biomedical Research and Innovation Research, Institute for Clinical 
Research, National Hospital Organization Osaka National Hospital, 
Osaka, Osaka, Japan, 25Department of Neurosurgery, Yamagata University 
School of Medicine, Yamagata, Japan, 26Department of Neurosurgery, 
Kyorin University Faculty of Medicine, Tokyo, Japan, 27Department of 
Neuro-Oncology/Neurosurgery, Saitama Medical University International 
Medical Center, Hidaka, Saitama, Japan, 28Division of Brain Tumor 
Translational Research, National Cancer Center Research Institute, 
Chuo-ku, Tokyo, Japan
TERT promoter mutation is associated with 1p/19q codeletion and fa-
vorable prognosis in IDH-mutated gliomas. Prognostic and diagnostic sig-
nificance of TERT promoter mutation is well-recognized in IDH-wildtype 
glioblastomas, but not in IDH-mutated gliomas. We investigated prognostic 
efficacy of TERT mutation in a cohort of 560 Japanese IDH-mutated adult 
gliomas. The molecular status of IDH, TERT and 1p/19q and patient clin-
ical data including Karnofsky performance status (KPS) were collected in 
all cases. TERT mutations and 1p/19q codeletions were found in 303 and 
285 cases, respectively. The patient cohort was divided into four groups by a 
combination of the 1p/19q and TERT status. The characteristics of 1p/19q 
intact-TERT mutated group (Astro-TERT group, n=24) were compared 
with those of 1p/19q intact-TERT wild (Astro-group, n=251) or 1p/19q 
codeleted-TERT mutated (Oligo-group, n=279) cases. Astro-TERT group 
with any grade showed intermediate overall survival between the Oligo-
group and Astro-group although the survival differences were not statistic-
ally significant (median overall survival (OS) not reached (NR) versus NR, 
and 106 months, respectively. p >0.05). We further conducted subgroup ana-
lysis by adjusting KPS and WHO grade as Cox regression analysis for sur-
vival indicated the unfavorable survival impact of KPS < 90 and WHO grade 
IV. In the subgroup with favorable KPS (90–100) and grade II-III (n=438), 
The OS of Astro-TERT group (median NR) was significantly longer survival 
than that of Astro-group (median 120.2 months, p=0.032), and was com-
parable with that of the Oligo-group (median NR, p >0.05). On the other 
hand, OS of none of the molecular groups significantly differ in poorer KPS 
subgroups (p >0.05). In grade IV tumors, the OS of the Astro-TERT group 
(NR) was comparable with that of Astro-group (29 months, p=0.19) rather 
than Oligo-group (NR, p=0.051). Thus, TERT promoter status provides a 
valuable prognostic information for IDH-mutated grade II-III gliomas in the 
current molecular diagnostic system.
PATH-38. ROSETTE-FORMING GLIONEURONAL TUMOR 
IS DEFINED BY FGFR1 ACTIVATING ALTERATIONS WITH 
FREQUENT ACCOMPANYING PI3K AND MAPK PATHWAY 
MUTATIONS
Lucas Calixto-Hope1, Julieann Lee1, Emily Sloan1, Jeffrey Hofmann1, 
Jessica Van Ziffle1, Courtney Onodera1, James Grenert1, Patrick Devine1,  
Cassie Kline1, Anu Banerjee1, Jennifer Clarke1, Jennie Taylor2, 
Nancy Ann Oberheim-Bush1, Robin Buerki7, Nicholas Butowski1, 
Susan Chang1, Mike McDermott1, Manish Aghi1, Philip Theodosopoulos3,  
Shawn Hervey-Jumper3, Mitchel Berger1, Corey Raffel1, Nalin Gupta4, 
Bette Kleinschmidt-DeMasters5, Matthew Wood6, Marjorie Grafe6, 
Hua Guo7, Peter Sun7, Joseph Torkildson7, Tabitha Cooney1,  
Cynthia Fata8, David Scharnhorst8, David Samuel8, Serguei Bannykh9, 
Ziad Khatib9, Ossama Maher9, Gabriel Chamyan9, Liset Pelaez9, 
Carole Brathwaite9, Lee-way Jin10, Mirna Lechpammer10, Donald Born11,  
Hannes Vogel12, Han Lee13, Joanna Phillips3, Melike Pekmezci1, 
Andrew Bollen1, Tarik Tihan1, Arie Perry1, and David Solomon1; 
1University of California, San Francisco, San Francisco, CA, USA, 
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2Division of Neuro-Oncology UCSF, San Francisco, CA, USA, 3Department 
of Neurological Surgery, University of California, San Francisco, San 
Francisco, CA, USA, 4University of California, San Francisco, Department 
of Neurological Surgery, Department of Pediatrics, San Francisco, CA, USA, 
5University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 
6Oregon Health & Science University, Portland, OR, USA, 7UCSF Benioff 
Children’s Hospital Oakland, Oakland, CA, USA, 8Valley Children’s 
Hospital, Madera, CA, USA, 9Cedars-Sinai Medical Center, Los Angeles, 
CA, USA, 9Nicklaus Children’s Hospital, Miami, FL, USA, 10University 
of California, Davis, Sacramento, CA, USA, 11Stanford University, Palo 
Atlo, CA, USA, 12Stanford University, Stanford, CA, USA, 13Sutter Health, 
Sacramento, CA, USA
BACKGROUND: Rosette-forming glioneuronal tumor (RGNT) is an 
uncommon CNS tumor originally described in the fourth ventricle char-
acterized by a low-grade glial neoplasm admixed with a rosette-forming 
neurocytic component.   METHODS: We reviewed clinicopathologic fea-
tures of 42 patients with RGNT. Targeted next-generation sequencing 
was performed, and genome-wide methylation profiling is underway.  RE-
SULTS: The 20 male and 22 female patients had a mean age of 25 years 
(range 3–47) at time of diagnosis. Tumors were located within or adjacent 
to the lateral ventricle (n=16), fourth ventricle (15), third ventricle (9), and 
spinal cord (2). All 31 tumors assessed to date contained FGFR1 activating 
alterations, either in-frame gene fusion, kinase domain tandem duplication, 
or hotspot missense mutation in the kinase domain (p.N546 or p.K656). 
While 7 of these 31 tumors harbored FGFR1 alterations as the solitary 
pathogenic event, 24 contained additional pathogenic alterations within 
PI3-kinase or MAP kinase pathway genes: 5 with additional PIK3CA and 
NF1 mutations, 4 with PIK3CA mutation, 3 with PIK3R1 mutation (one 
of which also contained focal RAF1 amplification), 5 with PTPN11 muta-
tion (one with additional PIK3R1 mutation), and 2 with NF1 deletion. The 
other 5 cases demonstrated anaplastic features including hypercellularity 
and increased mitotic activity. Among these anaplastic cases, 3 harbored 
inactivating ATRX mutations and two harbored CDKN2A homozygous de-
letion, in addition to the FGFR1 alterations plus other PI3-kinase and MAP 
kinase gene mutations seen in those RGNT without anaplasia.  CONCLU-
SION: Independent of ventricular location, RGNT is defined by FGFR1 
activating mutations or rearrangements, which are frequently accompanied 
by mutations involving PIK3CA, PIK3R1, PTPN11, NF1, and KRAS. 
Whereas pilocytic astrocytoma and ganglioglioma are characterized by soli-
tary activating MAP kinase pathway alterations (e.g. BRAF fusion or muta-
tion), RGNT are genetically more complex with dual PI3K-Akt-mTOR and 
Ras-Raf-MAPK pathway activation. Rare anaplastic examples may show 
additional ATRX and/or CDKN2A inactivation.
PATH-39. DNA MISMATCH REPAIR ENZYME 
IMMUNOHISTOCHEMISTRY IS A RAPID, EFFECTIVE SCREENING 
TEST FOR HYPERMUTATED GLIOMAS
Matthew McCord, Alicia Steffens, Kwok-Ling Kam, Rodrigo Javier, 
Kathleen McCortney, and Craig Horbinski; Northwestern University, 
Chicago, IL, USA
BACKGROUND: While gliomas with hypermutated DNA are resistant 
to alkylating agents like temozolomide, they may be especially respon-
sive to immunotherapy, since they express abundant neoantigens on their 
cell surfaces. Screening for hypermutated gliomas is currently being done 
through next-generation sequencing (NGS) panels that cover large por-
tions of tumor DNA, although this is costly and access to such testing is 
not universal. Since hypermutated gliomas typically contain inactivating 
mutations in one of the main DNA mismatch repair (MMR) proteins, 
and cancers with an MMR mutation usually show loss of normal MMR 
protein, we sought to determine the feasibility of rapidly screening for 
hypermutated gliomas with an MMR immunohistochemistry (IHC) 
panel that is already in widespread use for colorectal adenocarcinomas.   
METHODS: Tumor mutation burden (TMB) was determined via NGS 
for 101 gliomas, including 64 GBMs, 24 grade II-III astrocytomas, 9 grade 
II-III oligodendrogliomas, and 4 grade I gliomas. IHC for MSH2, MSH6, 
MLH1, and PMS2 was performed and analyzed on all gliomas while 
blinded to mutation profile and TMB.  RESULTS: Seven of 101 gliomas 
(7%) showed loss of an MMR protein by IHC. All 7 had matching MMR 
gene mutations and were hypermutated (100%), defined as TMB >20 per 
megabase of DNA. Of the remaining 94 with intact MMR IHC, only 
one was hypermutated. That case had an inactivating splice region mu-
tation in another gene involved in DNA repair, ATM, although ATM 
is not part of the IHC panel originally developed for colorectal cancer. 
Overall sensitivity and specificity of the current MMR IHC panel for 
hypermutated gliomas was therefore 88% and 100%, respectively.  CON-
CLUSION: The colorectal MMR IHC panel, available in virtually all 
clinical IHC labs, is also a good screening test for hypermutated gliomas. 
Expansion of the panel to include even more DNA repair proteins, like 
ATM, would enhance its utility.
PATH-40. PROFILING PLEOMORPHIC XANTHROASTROCYTOMA 
WITH DNA METHYLATION AND EXPLORING THE TUMOR 
IMMUNE CELL-TYPE COMPOSITION WITH METHYLATION-
BASED DECONVOLUTION
Karen Tang, David Kurland, Varshini Vasudevaraja,  
Jonathan Serrano, Alireza Radmanesh, and Matija Snuderl; New York 
University Langone Health, New York, NY, USA
INTRODUCTION: Pleomorphic xanthoastrocytoma (PXA) is a rare 
type of brain tumor that commonly affects children and young adults. PXAs 
are typically characterized by tumor lymphocytic infiltration, but the signifi-
cance of the tumor immune microenvironment has not yet been well-defined. 
In this study, we correlated DNA methylation profiling of PXAs with clinical 
outcome and explored the tumor microenvironment by analyzing inflamma-
tory cell populations.  METHODS: We retrospectively analyzed 30 tumor 
samples, of which 21 tumor samples from 18 subjects had a diagnosis of 
PXA both by DNA methylation and by histology. MethylCIBERSORT was 
used to deconvolute PXA inflammatory cell populations and compare them 
with inflammatory cell populations in previously published cohorts of IDH 
wildtype glioblastoma and ganglioglioma samples.  RESULTS: Median age 
at diagnosis was 16 years (range 7–32). 3-year and 5-year overall survival 
(OS) was 73% and 71% respectively. CDKN2A/B deletion was noted in 
15 out of 18 subjects (83%). 10 out of the 12 subjects (83%) that had 
testing for BRAFV600E showed the mutation. CDKN2A/B deletion and 
Trisomy 7 did not show any significant association with overall survival 
(p = 0.39 and p = 0.69). Decreased survival was observed in subjects with 
tumors lacking the BRAFV600E mutation (p = 0.03). PXAs were observed 
to have significantly increased CD8 T-cell epigenetic signatures compared to 
gangliogliomas (p = 0.0019) and significantly increased CD8 T-cell and CD19 
B-cell signatures compared to IDH wildtype glioblastomas (p = 0.0011 and 
p = 0.0011).  CONCLUSION: This research suggests that PXAs have a dis-
tinct methylation profile that correlates with clinical outcome. PXAs show 
significant upregulation of CD8 T-cell epigenetic signatures compared to 
gangliogliomas and significant upregulation of CD8 T-cell and CD19 B-cell 
epigenetic signatures compared to IDH wildtype glioblastomas. This distinct 
characterization of immune cell-types in PXAs could have an impact on fu-
ture development of immunotherapy.
PATH-41. LONGITUDINAL MATCHED MUTATIONAL ANALYSIS IN 
RECURRENT AND MULTIFOCAL GLIOMAS
Ahmad Daher; Hartford HealthCare Medical Group, Hartford, CT, USA
Re-resection of recurrent gliomas and multifocal gliomas are relatively 
uncommon resulting in limited understanding of the molecular profile of 
gliomas in those settings. Here we present a comprehensive mutational ana-
lysis via next generation sequencing (NGS) of 20 gliomas from 9 patients 
treated at our institution: one recurrent oligodendroglioma, one secondary 
glioblastoma (GBM), five locally recurrent primary GBMs, and two multi-
focal recurrent primary GBMs. Tumor mutational burden (TMB) range was 
1.8–60.6 mutations/megabase (mt/Mb). Elevated TMB was seen in the ini-
tial (49.2 mt/Mb) and recurrent (60.6 mt/Mb) secondary GBM samples and 
in the distal recurrent GBM sample (50.9 mt/Mb) of one of the two pa-
tients with multifocal recurrent disease, suggesting a temozolomide-induced 
hypermutated state. Interestingly, the elevated TMB in the patient of multi-
focal recurrence occurred 5 years after completing 12 cycles of TMZ and 
was seen in the distal but not local focus of disease recurrence where TMB 
remained at 1.8 mt/Mb. The patient with multifocal (right frontal and right 
temporal) GBM at diagnosis developed recurrence in the temporal location 
only. NGS of the 2 resected tumors revealed 4 common somatic mutations, 
3 mutations unique to the right frontal lesion and 8 mutations unique to the 
right temporal lesion. Additionally, our oligodendroglioma who was heavily 
treated in the six years prior to his last recurrence retained 4/6 of the ini-
tial somatic mutations and acquired 5 new ones upon the last recurrence. 
This analysis further highlights glioma spatiotemporal heterogeneity and the 
linear and divergent evolution upon disease recurrence and in the multifocal 
pre-treatment and recurrent settings. We also show that extensive oncogenic 
alterations can occur upon glioma recurrence, which is a major therapeutic 
barrier in managing recurrent disease, a barrier that can render the initial 
genomic profile of the disease, the basis of molecularly targeted therapy in 
the majority of cases, less meaningful.
PATH-42. IDH-MUTANT LOWER-GRADE ASTROCYTOMAS CAN 
BE STRATIFIED FOR RISK BY CDKN2A, CDK4 AND PDGFRA COPY 
NUMBER ALTERATIONS
Ryan Rui Yang, Kay Ka-Wai Li, and Ho-Keung Ng; The Chinese University 
of Hong Kong, Hong Kong
In the 2016 WHO classification of tumors of the CNS, isocitrate dehydro-
genase (IDH) mutation is a main classifier for lower-grade astrocytomas 
and IDH mutated astrocytomas is now regarded as a single group with 
good prognosis. However, the molecular and clinical heterogeneity among 
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